Similar articles

• Should it be easier or harder to use unapproved drugs and devices?

  Flannery EJ. Flannery EJ. Hastings Cent Rep. 1986 Feb;16(1):17-23. Hastings Cent Rep. 1986. PMID: 3514546 Clinical Trial.
• [The observational post-marketing study--an observation of use].

  Meister W. Meister W. Dtsch Med Wochenschr. 2003 Apr 17;128(16):859-62. doi: 10.1055/s-2003-38705. Dtsch Med Wochenschr. 2003. PMID: 12701030 German. No abstract available.
• [Is there any leeway for assessment beyond randomised clinical trials?].

  Grell L. Grell L. Z Arztl Fortbild Qualitatssich. 2004 Sep;98(6):481-7. Z Arztl Fortbild Qualitatssich. 2004. PMID: 15527191 German.
• Statistical and regulatory issues in nonrandomized medical device clinical studies.

  Li H, Yue LQ. Li H, et al. J Biopharm Stat. 2008;18(1):20-30. doi: 10.1080/10543400701668233. J Biopharm Stat. 2008. PMID: 18161539 Review.
• An outline for public registration of clinical trials evaluating medical devices.

  Popp RL, Lorell BH, Stone GW, Laskey W, Smith JJ, Kaplan AV. Popp RL, et al. J Am Coll Cardiol. 2006 Apr 18;47(8):1518-21. doi: 10.1016/j.jacc.2005.09.079. Epub 2006 Mar 27. J Am Coll Cardiol. 2006. PMID: 16630985